[A26-18] Teprotumumab (thyroid eye disease) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-18
Commission:
Commission awarded on 02.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with moderate to severe thyroid eye disease
Result of dossier assessment:
- Patients in the acute disease phase receiving first-line treatment: added benefit not proven
- Patients in the acute disease phase who are eligible for second-line treatment: added benefit not proven
- Patients in the chronic disease phase: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-18